CH Biotech R&D CoTPE:6534 +0.33%84 Days Payable is 10.96 as of Dec. 2025, which is 25% below its 10-year median of 14.53. GuruFocus rates TPE:6534 with a GF Score™ of 84/100 and a GF Value™ of NT$100.55 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 244 Agriculture companies, CH Biotech R&D Co ranks worse than 94.67% on this metric.
The historical rank and industry rank for CH Biotech R&D Co's Days Payable or its related term are showing as below:
TPE:6534'
s Days Payable Range Over the Past 10 Years
Min: 9.23 Med: 14.53 Max: 29.4
Current: 11.61
During the past 13 years, CH Biotech R&D Co's highest Days Payable was 29.40. The lowest was 9.23. And the median was 14.53.
TPE:6534's Days Payable is ranked worse than 94.67% of 244
companies
in the Agriculture industry
Industry Median: 72.7
vs TPE:6534: 11.61
CH Biotech R&D Co's Days Payable
declined
from Dec. 2024 (12.91) to Dec. 2025 (10.96).
It may suggest that CH Biotech R&D Coaccelerated paying its suppliers.
CH Biotech R&D Co Days Payable Related Terms
CH Biotech R&D Co Days Payable Historical Data
* Premium members only.
The historical data trend for CH Biotech R&D Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6534 vs CTVA, CF, MOS: Days Payable Comparison
For the Agricultural Inputs subindustry, CH Biotech R&D Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CH Biotech R&D Co Days Payable vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, CH Biotech R&D Co's Days Payable distribution charts can be found below:
* The bar in red indicates where CH Biotech R&D Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CH Biotech R&D Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CH Biotech R&D Co (TPE:6534) has a Days Payable of 10.96 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CH Biotech R&D Co and its competitors. This is 25% below median its historical median of 14.53. Over the past decade, CH Biotech R&D Co's Days Payable has ranged from 9.23 to 29.40. According to the industry distribution chart, CH Biotech R&D Co ranks #231 out of 244 companies in the Agriculture industry, placing it in the top 94.7%.
Is CH Biotech R&D Co's Days Payable too high?
CH Biotech R&D Co's current Days Payable of 10.96 is 25% below median its 10-year median of 14.53. Over the past 10 years, this metric has ranged from a low of 9.23 to a high of 29.40. The Agriculture industry median Days Payable is 72.70. CH Biotech R&D Co's value of 10.96 is 84.9% below this industry median. Based on the distribution chart, CH Biotech R&D Co ranks #231 out of 244 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Days Payable compare to CTVA and CF?
According to the Agriculture industry distribution chart, CH Biotech R&D Co ranks #231 out of 244 companies for Days Payable. This places CH Biotech R&D Co in the lower half of its industry. The industry median Days Payable is 72.70. CH Biotech R&D Co's value of 10.96 is 84.9% below this benchmark. Historically, CH Biotech R&D Co's own Days Payable has ranged from 9.23 to 29.40 over the past decade. While the company's 10-year median is 14.53 vs. the industry median of 72.70, CH Biotech R&D Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for an Agriculture company?
The median Days Payable among Agriculture companies is 72.70, based on 244 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CH Biotech R&D Co's current Days Payable of 10.96 is 84.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CH Biotech R&D Co and its competitors. For the Agriculture industry, the median Days Payable is 72.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CH Biotech R&D Co's current Days Payable is 10.96, which is 25% below median its own 10-year median of 14.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$100.55, compared to a current price of NT$90.10 — trading 10.4% below its estimated fair value. The current Days Payable is 10.96, which is 25% below median its 10-year median of 14.53 and 84.9% below the Agriculture industry median of 72.70. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Days Payable is 10.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?
Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued.
The current stock price of NT$90.10 is trading 10.4% below its estimated GF Value™ of NT$100.55.
GuruFocus considers CH Biotech R&D Co to be Modestly Undervalued.
Key valuation signals for TPE:6534:
Days Payable: 10.96 (25% below median its 10-year median of 14.53)
GF Value™: NT$100.55 vs. price of NT$90.10 (10.4% below fair value)
Industry Position: 84.9% below the Agriculture median (#231 of 244)
No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score
Get the complete analysis for TPE:6534
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6534 has been successfully added to your 
